<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A dipeptidyl peptidase (DPP)-4 inhibitor, commonly used to treat patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, has caused concern because of immune system side effects </plain></SENT>
<SENT sid="1" pm="."><plain>We report a 48-year-old woman with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who was diagnosed with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) after continued <z:e sem="disease" ids="C0162323" disease_type="Disease or Syndrome" abbrv="">polyarthritis</z:e> and an increase in rheumatoid factor up to 86 IU/mL after three months of treatment with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, a DPP-4 inhibitor </plain></SENT>
<SENT sid="2" pm="."><plain>The shared <z:chebi fb="0" ids="53000">epitope</z:chebi> (SE)-containing human leukocyte antigen (HLA)-DRB1 alleles, which are important predisposing factors for RA, were positive </plain></SENT>
<SENT sid="3" pm="."><plain>RA might have been triggered by <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> due to a predisposing condition </plain></SENT>
</text></document>